Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Oslo - Delayed Quote NOK

Lytix Biopharma AS (LYTIX.OL)

5.18
-0.20
(-3.72%)
As of 10:41:55 AM GMT+2. Market Open.
Currency in NOK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
11,133
11,133
3,991
11,031
19,307
Operating Expense
107,030
107,030
100,776
76,696
67,293
Operating Income
-95,897
-95,897
-96,785
-65,665
-47,986
Net Non Operating Interest Income Expense
1,712
1,712
4,879
1,875
78
Pretax Income
-94,265
-94,265
-87,897
-56,069
-48,079
Net Income Common Stockholders
-94,265
-94,265
-87,897
-56,069
-48,079
Diluted NI Available to Com Stockholders
-94,265
-94,265
-87,897
-56,069
-48,079
Basic EPS
-1.72
-1.74
-2.19
-1.41
-1.45
Diluted EPS
-1.72
-1.74
-2.19
-1.41
-1.45
Basic Average Shares
68,159.43
54,133.87
40,068.32
39,667.71
33,194.65
Diluted Average Shares
68,159.43
54,133.87
40,068.32
39,667.71
33,194.65
Total Operating Income as Reported
-95,896
-95,896
-96,785
-65,666
-47,985
Total Expenses
107,030
107,030
100,776
76,696
67,293
Net Income from Continuing & Discontinued Operation
-94,265
-94,265
-87,897
-56,069
-48,079
Normalized Income
-94,265
-94,265
-87,897
-56,069
-48,079
Interest Income
1,510
1,510
2,351
1,406
138
Interest Expense
126
126
56
146
66
Net Interest Income
1,712
1,712
4,879
1,875
78
EBIT
-94,139
-94,139
-87,841
-55,923
-48,013
EBITDA
-93,224
-93,224
-86,879
-55,004
-47,560
Reconciled Depreciation
915
915
962
919
453
Net Income from Continuing Operation Net Minority Interest
-94,265
-94,265
-87,897
-56,069
-48,079
Normalized EBITDA
-93,224
-93,224
-86,879
-55,004
-47,560
12/31/2021 - 6/14/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PCIB.OL PCI Biotech Holding ASA
1.3150
+1.15%
 
4FR.F Faron Pharmaceuticals Oy
2.4000
-2.64%
 
BGBIO.OL BerGenBio ASA
1.7540
-3.52%
 
ZLNA.OL Zelluna ASA
16.20
-4.69%
 
1VT.F Viking Therapeutics, Inc.
22.01
+0.85%
 
CANTA.ST Cantargia AB (publ)
1.5580
-0.51%
 
FLUO.ST FluoGuide A/S
39.10
-0.76%
 
VRCA Verrica Pharmaceuticals Inc.
0.4587
-1.99%
 
VYNE VYNE Therapeutics Inc.
1.8400
-1.08%
 
IBO Impact BioMedical Inc.
0.4258
+0.34%